www.fdanews.com/articles/123827-if-approved-fda-drug-labeling-could-decide-success-of-afrezza
If Approved, FDA Drug Labeling Could Decide Success of Afrezza
January 20, 2010
The U.S. Food and Drug Administration’s (FDA) delay in completing
its review of MannKind Corp.’s
ultra rapid-acting insulin therapy, called Afrezza, by the expected action date of January 16 has added to uncertainty over the commercial prospects of this experimental
inhaled insulin.
BNET
BNET